HT
PCRX icon

Headlands Technologies’s Pacira BioSciences PCRX Stock Holding History

Headlands Technologies’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,082
Closed -$95.7K – 1421
2024
Q4 		$95.7K Sell
5,082
-3,293
-39% -$57.8K 0.01% 675
2024
Q3 		$126K Buy
+8,375
New +$143K 0.01% 625
2024
Q2 		– Sell
-463
Closed -$13.5K – 1498
2024
Q1 		$13.5K Buy
+463
New +$14.2K ﹤0.01% 987
2023
Q4 		– Sell
-1,831
Closed -$56.2K – 1216
2023
Q3 		$56.2K Sell
1,831
-1,424
-44% -$51.3K 0.03% 419
2023
Q2 		$130K Buy
+3,255
New +$135K 0.04% 347

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Headlands Technologies's PCRX Position: Q1 2025 in Review

Headlands Technologies sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 5,082 shares — an estimated $95.7K sold.

Headlands Technologies first reported a position in PCRX in Q2 2023 and held it in 5 quarters. The position peaked at $130K in Q2 2023. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Headlands Technologies reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Headlands Technologies sold 5,082 Pacira BioSciences shares in Q1 2025, an estimated $95.7K.
  • Headlands Technologies first reported a position in Pacira BioSciences in Q2 2023 and held it in 5 quarters.
  • Headlands Technologies's Pacira BioSciences position peaked at $130K in Q2 2023.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Headlands Technologies's 13F filing for Q1 2025, filed 9 May 2025.